• Share
  • Email
  • Embed
  • Like
  • Private Content
What's Next in Vaccines?  HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016  Pipeline
 

What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline

on

  • 739 views

 

Statistics

Views

Total Views
739
Views on SlideShare
739
Embed Views
0

Actions

Likes
0
Downloads
7
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    What's Next in Vaccines?  HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016  Pipeline What's Next in Vaccines? HIV, Malaria, MRSA, and 30 Other Vaccine Targets in the 2010-2016 Pipeline Document Transcript

    • Get more info on this report!Whats Next in Vaccines? HIV, Malaria, MRSA, and 30 Other VaccineTargets in the 2010-2016 PipelineFebruary 1, 2010The global market for human vaccines has experienced strong growth in the past fewyears, and R&D departments at many pharmaceutical companies are working on newprophylactics, some of which may see near-term marketing. What illnesses may see avaccine option in the coming years? Which vaccines will have the most successfulbusiness model? Who are the major companies in this market, and possible newentrants? What can current vaccine success stories tell us about the future of thevaccine market? This Kalorama Information report Whats Next in Vaccines? examinesand estimates the market for vaccines that have yet to be launched, including thefollowing target areas: Addiction Allergy Alzheimer’s Disease Anthrax Asthma Campylobacter Infection Chlamydia Croup Dengue Fever Diabetes Ebola Epstein-Barr Virus Enterotoxigenic Escherichia coli Helicobacter Pylori Hepatitis Herpesvirus Hookworm Hypertension HIV/AIDS Leishmaniasis
    • Malaria MRSA Infection Multiple Sclerosis Obesity Parainfluenza Virus Type 3 Parkinson’s Disease Plague Respiratory Syncytial Virus Ross River Virus Shigellosis Smoking Stroke Tuberculosis West Nile VirusSome of these vaccines may see success; some could be the blockbusters of thefuture. For marketers and industry watchers a knowledge of all of the potential vaccineswill be important to understand how pharma is seeking to renew bottom line withaggressive prophylactic strategies, and who the winners and losers in the near futuremay be. Alison Sahoo has looked at the vaccine market three times in as many yearsfor Kalorama Information, and in this report applies a knowledge of what companieshave done in the past to potential efforts.There are a number of trends that will impact the industry that market watchers will wantto know about, and Kalorama Information has covered these trends; including: NewVaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines,Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturingmethods and the approval process. In addition, the report focuses on the emergingvaccine activities of the following companies Acambis plc ACE BioSciences AFFiRiS ALK-Abello A/S Allergy Therapeutics Bavarian Nordic A/S Baxter Healthcare Celldex Therapeutics Crucell Cytos Biotechnology GlaxoSmithKline Hawaii Biotech Intercell Medimmune Merck & Co. Inc Mymetics
    • Nabi Biopharmaceuticals Novartis Opexa Therapeutics Paladin Labs Sanofi PasteurThis report provides forecasted revenues for products in development out to 2020. Thereport does not does not cover indication expansions of existing vaccine products, nordoes it cover vaccines for which products currently exist and are widely available, butmay need improvement. Development of vaccines that incorporate new productionmethods (such as the migration of chicken eggs to mammal, yeast or other cells) is alsoexcluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.Sales estimates for each market segment represent global revenues and are expressedin current dollars. Information for this report was gathered from a wide variety ofpublished sources including company reports and filings, government documents, legalfilings, trade journals, newspapers and business press, analysts’ reports and othersources.Additional InformationNew York, February 18, 2010 — In the not-too-distant future we could see diabetes,the seventh leading cause of death in the U.S., treated with a vaccine. Several vaccinecandidates are in the pipeline, creating a possible $2.4 billion market for diabetesvaccine products by 2020, according to healthcare market research publisher KaloramaInformation, who recently published a survey of emerging vaccine products titled:What’s Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other VaccineTargets in the 2010-2020 Pipeline.Type I diabetes currently afflicts 35,000 people in the U.S. and about 700,000 peopleworldwide each year. Type II diabetes affects more than 16 million Americans and over200 million people worldwide.Currently, other than a humanized anti-CD3 antibody with considerable side effects,there is no other means to reverse new-onset type 1 diabetes. People with type IIdiabetes must control their blood sugar levels with diet and exercise, and approximately78% also take prescription medications to help control their diabetes. However, theyremain at risk for a large number of associated conditions including foot ulcers, heartdisease, kidney failure, and various skin conditions.“Diabetes is a debilitating disease and a growing problem as waistlines continue toexpand,” said Bruce Carlson, publisher of Kalorama Information. “This is a desirablemarket for any drug maker, and it’s not surprising that the pipeline is full.”
    • There are at least seven diabetes vaccine candidates in development. Most are inPhase I testing and address type 1 diabetes. But one being developed by the Swedishcompany Diamyd Medical is currently in a global Phase III trial, which includes 640children and adolescents newly diagnosed with type 1 diabetes. The purpose of thePhase III trial is to confirm and evaluate the ability of the Diamyd vaccine to arrest orslow the autoimmune destruction of the bodys insulin-producing cells, therebypreserving the bodys own ability to produce insulin. Initial analysis of data from thePhase II trial showed that patients treated with the Diamyd vaccine early after diagnosishave a clearly better diabetes status compared to the corresponding placebo group, 4years after the injections.Kalorama predicts a $100 million market from diabetes vaccines by 2012 as the firstproduct currently in Phase III trials enters the market, with growth amounting to $2.4billion by 2020 as other products reach market.Kalorama Information’s What’s Next in Vaccines? HIV, Malaria, Rabies, MRSA, and30 Other Vaccine Targets in the 2010-2020 Pipeline. forecasts emerging vaccinemarkets through 2020, previews the product pipeline and details the major players inthe industry.About Kalorama InformationKalorama Information supplies the latest in independent market research in the lifesciences, as well as a full range of custom research services.Table of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Overview Emerging Vaccines and Forecasts The Global Market for Emerging VaccinesCHAPTER TWO: INTRODUCTION TO VACCINES A Brief History: The Development of Vaccines The Immune Response Mechanism of Action Types of Vaccines Attenuated (Weakened) Live Viruses Killed (Inactivated) Viruses Toxoid Vaccines Genetically Engineered/Modified Vaccines Bacteria-Based Vaccines Subunit Vaccines Conjugate Vaccines DNA Vaccination
    • Vaccine Approval Process Trends Driving the Vaccines MarketCHAPTER THREE: EMERGING VACCINES Introduction Emerging Vaccines by Disease Area Addiction Smoking Allergy Alzheimer’s Disease Anthrax Asthma Campylobacter Infection Chlamydia Croup Dengue Fever Diabetes Ebola Epstein-Barr Virus Enterotoxigenic Escherichia coli Heart Attack Helicobacter Pylori Hepatitis Hepatitis C Hepatitis E Herpesvirus Hookworm Hypertension HIV/AIDS Leishmaniasis Malaria MRSA Infection Multiple Sclerosis Obesity Parainfluenza Virus Type 3 Parkinson’s Disease Plague Respiratory Syncytial Virus Ross River Virus Shigellosis Stroke Tuberculosis West Nile VirusCHAPTER FOUR: EMERGING VACCINES MARKET FORECAST Global Market for Emerging Vaccines Emerging Vaccines Market Segment Forecasts
    • Addiction Allergies Alzheimer’s Disease Anthrax Asthma Campylobacter Infection Chlamydia Croup Dengue Fever Diabetes Ebola EBV Infection ETEC Infection Heart Attack H. Pylori Infection Hepatitis C and E Herpesvirus Infection Hookworm Hypertension HIV/AIDS Leishmaniasis Malaria MRSA Infection Multiple Sclerosis Obesity PIV-3 Infection Parkinson’s Disease Plague RSV Infection Ross River Virus Infection Shigellosis Stroke Tuberculosis West Nile VirusCHAPTER FIVE: ISSUES AND TRENDS New Vaccine Technologies DNA Vaccination Innovative Delivery Systems Edible Vaccines Mucosal Delivery Intranasal Delivery Vaccine Patches Funding ShortfallsCHAPTER SIX: COMPANY PROFILES Acambis plc
    • History and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationACE BioSciencesHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationAFFiRiSHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationALK-Abello A/SHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationAllergy TherapeuticsHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationBavarian Nordic A/SHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationBaxter HealthcareHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationCelldex TherapeuticsHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationCrucellHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationCytos BiotechnologyHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancialGlaxoSmithKlineHistory and Lines of BusinessEmerging Vaccine ActivitiesFinancial InformationHawaii BiotechHistory and Lines of BusinessEmerging Vaccine Products
    • Financial Information Intercell History and Lines of Business Emerging Vaccine Products Financial Information Medimmune History and Lines of Business Emerging Vaccine Products Financial Information Merck & Co. Inc History and Lines of Business Emerging Vaccine Activities Financial Information Mymetics History and Lines of Business Emerging Vaccine Products Financial Information Nabi Biopharmaceuticals History and Lines of Business Emerging Vaccine Activities Financial Information Novartis History and Lines of Business Emerging Vaccine Activities Financial Information Opexa Therapeutics History and Lines of Business Emerging Vaccine Activities Financial Information Paladin Labs History and Lines of Business Emerging Vaccine Activities Financial Information Sanofi Pasteur History and Lines of Business Emerging Vaccine Activities Financial InformationAppendixCompany DirectoryLIST OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: Status of Emerging Vaccines by DiseaseCHAPTER TWO: INTRODUCTION TO VACCINES
    • Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2008 Table 2-2: Vaccine-Preventable Diseases, December 2009 Table 2-3: VAERS Table of Reportable Events Following VaccinationCHAPTER THREE: EMERGING VACCINES Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines Table 3-1: Emerging Vaccines by Disease and Stage of Testing Figure 3-3: Comparative Severity Ranking of Addiction Figure 3-4: Comparative Severity Ranking of Allergy Figure 3-5: Comparative Severity Ranking of Alzheimer’s Disease Figure 3-6: Comparative Severity Ranking of Anthrax Figure 3-7: Comparative Severity Ranking of Asthma Figure 3-8: Comparative Severity Ranking of Campylobacter Infection Figure 3-9: Comparative Severity Ranking of Chlamydia Figure 3-10: Comparative Severity Ranking of Croup Figure 3-10: Comparative Severity Ranking of Dengue Fever Figure 3-12: Comparative Severity Ranking of Diabetes Figure 3-13: Comparative Severity Ranking of Ebola Figure 3-14: Comparative Severity Ranking of EBV Figure 3-15: Comparative Severity Ranking of ETEC Figure 3-16: Comparative Severity Ranking of Heart Attack Figure 3-17: Comparative Severity Ranking of H. Pylori Infection Figure 3-10: Comparative Severity Ranking of Hepatitis C and E Figure 3-19: Comparative Severity Ranking of Herpesvirus Infection Figure 3-20: Comparative Severity Ranking of Hookworm Figure 3-21: Comparative Severity Ranking of Hypertension Figure 3-10: Comparative Severity Ranking of HIV/AIDS Figure 3-23: Comparative Severity Ranking of Leishmaniasis Figure 3-24: Comparative Severity Ranking of Malaria Figure 3-25: Comparative Severity Ranking of MRSA Infection Figure 3-26: Comparative Severity Ranking of Multiple Sclerosis Figure 3-27: Comparative Severity Ranking of Obesity Figure 3-28: Comparative Severity Ranking of PIV-3 Infection Figure 3-29: Comparative Severity Ranking of Parkinson’s Disease Figure 3-30: Comparative Severity Ranking of Plague Figure 3-31: Comparative Severity Ranking of RSV Infection Figure 3-32: Comparative Severity Ranking of Ross River Virus Infection Figure 3-33: Comparative Severity Ranking of Shigellosis Figure 3-34: Comparative Severity Ranking of Stroke Figure 3-35: Comparative Severity Ranking of Tuberculosis Figure 3-36: Comparative Severity Ranking of West Nile Virus InfectionCHAPTER FOUR: EMERGING VACCINES MARKET FORECAST Table 4-1: World Market for Emerging Vaccines by Type, 2009-2020
    • Table 4-2: World Market for Emerging Vaccines by Type, 2009-2020 Table 4-3: World Addiction Vaccine Market 2009-2020 Table 4-4: World Allergy Vaccine Market 2009-2020 Table 4-5: World Alzheimer’s Disease Vaccine Market 2009-2020 Table 4-6: World Anthrax Vaccine Market 2009-2020 Table 4-7: World Asthma Vaccine Market 2009-2020 Table 4-8: World Campylobacter Infection Vaccine Market 2009-2020 Table 4-9: World Chlamydia Vaccine Market 2009-2020 Table 4-10: World Croup Vaccine Market 2009-2020 Table 4-11: World Dengue Fever Vaccine Market 2009-2020 Table 4-12: World Diabetes Vaccine Market 2009-2020 Table 4-13: World Ebola Vaccine Market 2009-2020 Table 4-14: World EBVVaccine Market 2009-2020 Table 4-15: World ETECVaccine Market 2009-2020 Table 4-16: World Heart Attack Vaccine Market 2009-2020 Table 4-17: World H. Pylori Vaccine Market 2009-2020 Table 4-18: World Hepatitis C and E Vaccine Market 2009-2020 Table 4-19: World Herpesvirus Vaccine Market 2009-2020 Table 4-20: World Hookworm Vaccine Market 2009-2020 Table 4-21: World Hypertension Vaccine Market 2009-2020 Table 4-22: World HIV/AIDS Vaccine Market 2009-2020 Table 4-23: World Leishmaniasis Vaccine Market 2009-2020 Table 4-24: World Malaria Vaccine Market 2009-2020 Table 4-25: World MRSA Vaccine Market 2009-2020 Table 4-26: World Multiple Sclerosis Vaccine Market 2009-2020 Table 4-27: World Obesity Vaccine Market 2009-2020 Table 4-28: World PIV-3 Vaccine Market 2009-2020 Table 4-29: World Parkinson’s Disease Vaccine Market 2009-2020 Table 4-30: World Plague Vaccine Market 2009-2020 Table 4-31: World RSV Vaccine Market 2009-2020 Table 4-32: World Ross River Virus Vaccine Market 2009-2020 Table 4-33: World Shigellosis Vaccine Market 2009-2020 Table 4-34: World Stroke Vaccine Market 2009-2020 Table 4-35: World Tuberculosis Vaccine Market 2009-2020 Table 4-36: World West Nile Virus Vaccine Market 2009-2020Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2578515US: 800.298.5699
    • UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004